查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1938876

心臟衰竭藥物市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類別、通路、地區及競爭格局分類，2021-2031年）

Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球心臟衰竭藥物市場預計將從 2025 年的 84.7 億美元成長到 2031 年的 122.8 億美元，年複合成長率為 6.39%。

此類別涵蓋多種藥物，例如利尿劑和血管收縮素轉化酵素抑制劑，旨在提高心臟效率並緩解臨床症狀。推動這一成長的關鍵因素是全球人口快速老化以及高血壓和糖尿病等合併症盛行率的不斷上升，這兩者都會增加心臟衰竭的風險。日益加重的疾病負擔推動了對先進治療方法的巨大需求，並促進了新型藥物療法的持續研發。例如，美國心臟衰竭協會 (HFSA) 估計，到 2024 年，美國將有約 670 萬成年人患有心臟衰竭。

市場概覽
預測期 2027-2031
市場規模：2025年 84.7億美元
市場規模：2031年 122.8億美元
複合年成長率：2026-2031年 6.39%
成長最快的細分市場 零售藥房
最大的市場 北美洲

新興藥物和先進治療方法的高昂成本是市場擴張的一大障礙。在許多開發中國家，有限的醫療報銷預算限制了患者獲得這些昂貴藥物的機會，往往迫使醫療服務提供者依賴價格較低的學名藥來治療患者。因此，這些資金限制了創新型心臟衰竭治療藥物生產商的商機，並減緩了全球市場的整體發展。

市場促進因素

全球心臟衰竭盛行率不斷上升以及人口快速老化是市場擴張的關鍵促進因素。預期壽命延長增加了心臟衰竭的累積風險，從而形成了一個需要長期管理的龐大患者群體。文明病相關合併症的增加進一步加劇了這種人口結構變化，加速了疾病進展，並增加了對醫療干預的需求。根據美國心臟衰竭協會2024年9月發布的報告《2024年心臟衰竭統計：心臟衰竭流行病學和預後統計》，預計到2050年，美國成年心臟衰竭患者人數將達到1140萬，這一激增與對有效治療性介入日益成長的迫切需求直接相關。

同時，新型藥物治療方法和藥物類別的進步正在從根本上改變治療模式。血管收縮素受體/腦啡肽酶抑制劑和鈉-葡萄糖共同輸送體2抑制劑等創新藥物的引入，與傳統治療方法相比，帶來了更優的臨床療效，從而促進了其在臨床上的廣泛應用。製藥公司正利用這些科學突破，將高價值療法商業化，以佔據可觀的市場佔有率。例如，諾華在2023年度報告（2024年1月發布）中披露，其心臟衰竭治療藥物Entresto的銷售額成長了30%，達到60億美元。同時，勃林格殷格翰在其2023年度報告（2024年4月發布）中披露，其藥物Jardiance的銷售額達到74億歐元，這充分展現了這些現代治療領域巨大的商業性影響力。

市場挑戰

新興藥物和先進治療方法帶來的巨額經濟成本是全球心臟衰竭治療市場的主要阻礙因素。創新藥物往往定價高昂，超越公共醫療預算和報銷體系的負擔能力，尤其是在開發中國家。當醫療體系面臨如此嚴峻的財政困境時，醫療服務提供者往往被迫優先選擇價格較低的學名藥，而非新藥。這種趨勢直接限制了新型治療方法生產商的收入潛力，並減緩了臨床先進治療方法的商業性化應用。

此外，醫療基礎設施面臨的經濟負擔也阻礙了高成本藥物的廣泛應用。根據美國心臟協會預測，截至2024年，到2050年，美國心血管疾病的總成本預計將達到1.8兆美元。如此巨大的支出預測迫使支付方採取嚴格的成本控制措施。因此，由於報銷限制阻礙了患者獲得有效但昂貴的心臟衰竭治療方案，市場面臨持續的壓力。

市場趨勢

GLP-1促效劑在肥胖相關心臟衰竭治療中的應用，顯著改變了治療格局，使治療重點轉向那些會加重心臟衰竭的代謝併發症。這一趨勢標誌著治療策略從傳統的血流動力學管理轉向針對疾病系統性病因的治療方法，尤其適用於射血分數保留且BMI較高的患者。製藥公司正有效地利用這些藥物，降低越來越多患者群體的心血管風險，使其不再局限於簡單的體重管理，而是轉向臨床心血管保護。例如，在2024年3月發布的新聞稿中，諾和諾德宣布，在關鍵性SELECT試驗中，與安慰劑相比，2.4毫克Semaglutide可使主要心血管不利事件的風險降低20%，該試驗涉及FDA核准Wegovy上市。

此外，基因治療和再生醫學研發管線的興起，致力於為基因明確的心肌病提供根治性干預措施，將重點從症狀管理轉向解決潛在的分子病因。這種創新方法正透過病毒載體遞送系統的進步而獲得廣泛應用，這些系統旨在恢復心臟組織中的功能性蛋白質表現。該領域的臨床試驗已產生數據，支持長期結構改善和疾病逆轉的潛力。值得注意的是，2024年11月，Rocket Pharmaceuticals公司報告稱，其用於治療達農病的在臨床實驗基因療法在12個月時使左心室質量指數中位數降低了24%；該結果發表於《新英格蘭醫學雜誌》。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球心臟衰竭藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（ACE抑制劑、血管收縮素II受體阻斷劑、 BETA阻斷劑、利尿劑、醛固酮拮抗劑、強心藥、其他）
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美心臟衰竭藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲心臟衰竭藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區心臟衰竭藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲心臟衰竭藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲心臟衰竭藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球心臟衰竭藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co
  • Amgen Inc
  • Boehringer Ingelheim GmbH
  • Pfizer Inc
  • Johnson & Johnson
  • Eli Lilly and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19536

The Global Heart Failure Therapeutics Market is projected to expand from USD 8.47 Billion in 2025 to USD 12.28 Billion by 2031, reflecting a compound annual growth rate of 6.39%. This sector encompasses a wide variety of pharmaceutical agents, such as diuretics and angiotensin-converting enzyme inhibitors, which are designed to enhance cardiac efficiency and mitigate clinical symptoms. The primary catalysts driving this growth are the rapidly aging global population and the rising prevalence of comorbidities like hypertension and diabetes, both of which predispose individuals to cardiac insufficiency. This increasing disease burden generates substantial demand for advanced treatment options and fuels the continuous creation of novel pharmacotherapies; for instance, the Heart Failure Society of America estimated that approximately 6.7 million adults in the United States were living with heart failure in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.47 Billion
Market Size 2031USD 12.28 Billion
CAGR 2026-20316.39%
Fastest Growing SegmentRetail Pharmacies
Largest MarketNorth America

A significant barrier hindering the market's expansion is the high financial cost associated with emerging drug classes and advanced therapeutic regimens. In many developing nations, limited healthcare reimbursement budgets restrict patient access to these premium medications, often compelling healthcare providers to rely on older, lower-cost generic alternatives for patient care. Consequently, these economic constraints limit revenue opportunities for manufacturers of innovative heart failure drugs and slow the overall progression of the global market.

Market Driver

The escalating global prevalence of heart failure combined with a rapidly aging geriatric population acts as the primary engine for market expansion. As life expectancy rises, the cumulative risk of developing cardiac insufficiency increases, establishing a sustained patient base that requires long-term management. This demographic shift is further intensified by the growing incidence of lifestyle-related comorbidities, which accelerates disease progression and heightens the need for medical intervention. According to the Heart Failure Society of America's September 2024 report, 'HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics,' the number of adults living with heart failure in the United States is expected to reach 11.4 million by 2050, a surge that directly correlates with an increased urgency for effective therapeutic interventions.

Simultaneously, advancements in novel pharmacological therapies and drug classes are fundamentally reshaping the treatment landscape. The introduction of innovative agents, such as Angiotensin Receptor-Neprilysin Inhibitors and Sodium-Glucose Cotransporter-2 inhibitors, provides superior clinical outcomes compared to traditional regimens, thereby driving widespread clinical adoption. Pharmaceutical companies are capitalizing on these scientific breakthroughs by commercializing high-value therapeutics that capture significant market share. For example, Novartis reported in its 'Annual Report 2023' (January 2024) that sales of the heart failure drug Entresto increased by 30% to USD 6.0 billion, while Boehringer Ingelheim's 'Annual Report 2023' (April 2024) noted that sales of Jardiance reached EUR 7.4 billion, illustrating the commercial impact of these modern therapeutic classes.

Market Challenge

The substantial financial cost associated with emerging drug classes and advanced therapeutic regimens represents a primary restraint on the global heart failure therapeutics market. Innovative pharmaceutical agents often come with premium pricing that exceeds the capacity of public health budgets and insurance reimbursement plans, especially in developing nations. When healthcare systems encounter these strict financial limitations, providers are frequently forced to prioritize older, lower-cost generic alternatives over newer, patented medications. This trend directly restricts the revenue potential for manufacturers of novel therapies and decelerates the commercial adoption of clinically advanced treatments.

Furthermore, the economic burden placed on healthcare infrastructure creates a barrier to the widespread entry of high-cost drugs. According to the American Heart Association, the total cost of cardiovascular disease in the United States was projected in 2024 to potentially reach $1.8 trillion by 2050. This magnitude of projected expenditure forces payers to implement rigorous cost-containment measures. Consequently, the market faces sustained pressure as restricted reimbursement policies hamper the ability of patients to access effective but expensive heart failure management solutions.

Market Trends

The adoption of GLP-1 agonists for obesity-related heart failure is significantly altering the treatment landscape by targeting metabolic comorbidities that exacerbate cardiac insufficiency. This trend marks a departure from traditional hemodynamic modulation toward therapies that address systemic drivers of disease, particularly in patients with preserved ejection fraction and a high body mass index. Pharmaceutical developers are successfully leveraging these agents to mitigate cardiovascular risks in this expanding patient demographic, moving beyond simple weight management to clinical cardiovascular protection. For instance, Novo Nordisk announced in a March 2024 press release regarding Wegovy's FDA approval that the pivotal SELECT trial demonstrated semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared to placebo.

Additionally, the emergence of gene therapy and regenerative medicine pipelines is focusing on delivering curative interventions for genetically defined cardiomyopathies, shifting the focus from symptom management to addressing root molecular causes. This innovative approach is gaining traction through the advancement of viral vector-based delivery systems designed to restore functional protein expression in cardiac tissue. Clinical trials in this sector are producing data that validates the potential for long-term structural improvement and disease reversal; notably, Rocket Pharmaceuticals reported in November 2024 that its investigational gene therapy for Danon disease resulted in a median 24% reduction in left ventricular mass index at 12 months, as published in the New England Journal of Medicine.

Key Market Players

  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co
  • Amgen Inc
  • Boehringer Ingelheim GmbH
  • Pfizer Inc
  • Johnson & Johnson
  • Eli Lilly and Company

Report Scope

In this report, the Global Heart Failure Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Heart Failure Therapeutics Market, By Drug Class

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

Heart Failure Therapeutics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Heart Failure Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heart Failure Therapeutics Market.

Available Customizations:

Global Heart Failure Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Heart Failure Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Heart Failure Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Heart Failure Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Heart Failure Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Heart Failure Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel

7. Europe Heart Failure Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Heart Failure Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Heart Failure Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Heart Failure Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Heart Failure Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Heart Failure Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Heart Failure Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Heart Failure Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Heart Failure Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Heart Failure Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Heart Failure Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Heart Failure Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Heart Failure Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Heart Failure Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Heart Failure Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Heart Failure Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Heart Failure Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Heart Failure Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Heart Failure Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Heart Failure Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Heart Failure Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck & Co., Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Bristol-Myers Squibb Co
  • 15.6. Amgen Inc
  • 15.7. Boehringer Ingelheim GmbH
  • 15.8. Pfizer Inc
  • 15.9. Johnson & Johnson
  • 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer